Business Wire

CARBIOS

Share
Carbios Announces the Publication of an Article on Its Enzymatic Recycling Technology in the Prestigious Scientific Journal Nature

Regulatory News:

CARBIOS (Euronext Growth Paris: ALCRB) (Paris:ALCRB), a company pioneering new bio-industrial solutions to reinvent the lifecycle of plastic and textile polymers, announces the publication of an article in the prestigious scientific journal Nature, entitled “ An engineered PET-depolymerase to break down and recycle plastic bottles” . The article is co-authored by scientists at Carbios and at the Company’s renowned academic partner, the Toulouse Biotechnology Institute 1 (TBI).

The article describes the development of a novel enzyme, which can biologically depolymerize all polyethylene terephthalate (PET) plastic waste, followed by an extremely efficient recycling into new bottles. PET is the most common thermoplastic polymer and is used to manufacture bottles, polyester clothing fibers, food containers, and various thermoformed packaging and components. Carbios’ recycling process, the first of its kind, initiates a real transition to a circular economy and can better prevent plastic pollution from harming our oceans and planet. This innovative technology also paves the way for recycling PET fibers, another major challenge in guaranteeing a clean and protected environment for future generations.

Prof. Alain Marty, Carbios’ Chief Scientific Officer and co-author of the Nature article says: "I am very proud that Nature, one of the most highly respected scientific journals in the world, has validated the quality of the research led by Carbios and TBI laboratory scientists in developing a PET recycling enzyme and a revolutionary process. The results obtained confirm the industrial and commercial potential of the Company’s proprietary process, which will be tested in 2021 in our demonstration plant in the heart of the French Chemical Valley, near Lyon."

Sophie Duquesne, INRAE Researcher: “For any researcher, seeing its work recognized by the prestigious journal Nature is a true achievement. I am very proud of the work accomplished by the researchers at TBI and Carbios, whose collaborative efforts have led to the development of a sustainable solution to the end of life of plastics.”

Dr. Saleh Jabarin, Distinguished Professor at The University of Toledo, Ohio and a member of Carbios’ Scientific Committee: “It's a real breakthrough in the recycling and manufacturing of PET. Thanks to the innovative technology developed by Carbios, the PET industry will become truly circular, which is the goal for all players in this industry, especially brand-owners, PET producers and our civilization as a whole.”

Bertrand Piccard, Founder and President of the Solar Impulse Foundation: “I am very pleased that the scientific community recognizes one of the solutions labelled by the Solar Impulse Foundation as a financially profitable solution to protect the environment. The use of such technology is as logical as it is ecological!”

Nature, the highest Impact Factor scientific journal, recognizes the ground-breaking quality of the enzymatic engineering research being done by Carbios and TBI, that is paving the way to virtuous management of plastic waste. “Carbios is the first company to successfully combine the two scientific worlds of enzymology and plastics” , as Dr. Philippe Pouletty, CEO of Truffle Capital and Co-founder of Carbios , comments.

By leveraging many years of experience with a world-renowned team, Carbios and TBI are proud to have been able to increase the degradation yield of PET waste to 90% in 10 hours, a significant upswing from the initial degradation yield of 1% after several weeks. This paradigm shift in how effectively PET can be recycled, is leading toward a future circular economy technology applicable to all PET waste, which Carbios is proud to be spearheading.

To read the article in Nature, please find the link here:

https://www.nature.com/articles/s41586-020-2149-4

About Carbios:

Carbios is a green chemistry company whose innovations help address the environmental and sustainable development challenges facing manufacturers. Since its creation in 2011 by Truffle Capital , the Company has developed, through biotechnology, two industrial processes that revolutionize the biodegradation and recycling of polymers. These world-first innovations, made possible with the support of Bpifrance (THANAPLAST™ project), enable to optimize the performance and lifecycle of plastics and textiles by exploiting the properties of highly specific enzymes.

Carbios' economic development model is based on the industrialization and commercialization of its products and/or enzymes, technologies and bioprocesses through license concessions directly or through joint ventures to major industrial players or sectors concerned by the Company's innovations. As such, Carbios created the joint venture Carbiolice in September 2016, in partnership with Limagrain Ingredients and the SPI fund operated by Bpifrance. This company, of which Carbios has majority control, will exploit the first technology licensed by Carbios by producing enzymatic granules for the production of biodegradable and biobased plastics.

Carbios benefits from the qualification "Innovative Company" of Bpifrance allowing the eligibility of the Company's securities for the investment of Mutual Funds Placement in Innovation (FCPI). For more information, please visit: www.carbios.fr

Carbios is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.

About Truffle Capital:

Established in 2001, Truffle Capital is a leading European Venture Capital company, specializing in breakthrough life sciences and FinTech technologies. Truffle Capital supports the creation and growth of young innovative companies capable of becoming tomorrow’s leaders. Headed by Patrick Kron, chairman, alongside cofounders and co-CEOs Philippe Pouletty, MD, and Bernard-Louis Roques, Truffle Capital has raised over €1.1 billion and has supported over 75 companies in the digital technology and life sciences sectors.

For more information: www.truffle.com – Twitter: @trufflecapital

This press release does not constitute and cannot be regarded as constituting an offer to the public, an offer to sell or a subscription offer or as a solicitation to solicit a buy or sell order in any country.

Translation for information purposes only. In case of discrepancy between the French and the English version of this press release, the French version shall prevail.

1 : A mixed research unit INSA Toulouse, INRAE, CNRS.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse

Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye